PDCD6: A Potential Drug Target and Biomarker (G10016)

Target Name: PDCD6

NCBI ID: G10016

PDCD6

PDCD6: A Potential Drug Target and Biomarker

PDCD6 (Protamineur deaminase 6) is a protein that is expressed in various tissues and cell types in the human body. It is a member of the superfamily of NAD+-dependent enzymes, which are involved in the transfer of electrons in a variety of cellular processes. One of the key functions of PDCD6 is its role in the detoxification of ammonia, which is a toxic compound that can be generated, for example, in the liver due to the consumption of protein-containing foods.

PDCD6 has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because of its unique structure and the effects that it has on various cellular processes.

One of the key reasons why PDCD6 has potential as a drug target is its location on the surface of various cell types. PDCD6 is expressed in the liver, pancreas, and skeletal muscles, which are all key organs that are involved in the detoxification of ammonia. This means that any drug that targets PDCD6 is likely to have a more targeted and effective effect on those specific cells and organs.

Additionally, PDCD6's role in the detoxification of ammonia is a critical function that is involved in the regulation of various cellular processes. The levels of ammonia in the body can have a significant impact on the health and function of cells and organs, and PDCD6 plays a key role in keeping the levels of ammonia in the body under control.

Another potential reason why PDCD6 has been identified as a drug target is its involvement in the development and progression of various diseases. For example, PDCD6 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, PDCD6 has been linked to the development of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

PDCD6's role in the detoxification of ammonia has also been implicated in the development of certain types of cancer. For example, studies have shown that PDCD6 is often expressed in various types of cancer, and that its levels are associated with the development of those diseases. This suggests that targeting PDCD6 may be an effective way to prevent or treat certain types of cancer.

In addition to its potential as a drug target, PDCD6 has also been identified as a potential biomarker for a variety of diseases. For example, studies have shown that PDCD6 levels are often elevated in individuals with certain types of cancer, and that these levels can be used as a biomarker for the disease. Additionally, PDCD6 has been shown to be involved in the regulation of various cellular processes, and its levels can be used as a biomarker for the effects of certain drugs on those processes.

Overall, PDCD6 is a protein that has the potential to be a drug target and biomarker for a variety of diseases. Its unique structure and the effects it has on various cellular processes make it an attractive target for drug development, and its involvement in the detoxification of ammonia and the development and progression of various diseases make it a promising biomarker for diagnostic and therapeutic applications. Further research is needed to fully understand the role of PDCD6 in these processes and to develop effective treatments for the diseases associated with its dysfunction.

Protein Name: Programmed Cell Death 6

Functions: Calcium sensor that plays a key role in processes such as endoplasmic reticulum (ER)-Golgi vesicular transport, endosomal biogenesis or membrane repair. Acts as an adapter that bridges unrelated proteins or stabilizes weak protein-protein complexes in response to calcium: calcium-binding triggers exposure of apolar surface, promoting interaction with different sets of proteins thanks to 3 different hydrophobic pockets, leading to translocation to membranes (PubMed:20691033, PubMed:25667979). Involved in ER-Golgi transport by promoting the association between PDCD6IP and TSG101, thereby bridging together the ESCRT-III and ESCRT-I complexes (PubMed:19520058). Together with PEF1, acts as calcium-dependent adapter for the BCR(KLHL12) complex, a complex involved in ER-Golgi transport by regulating the size of COPII coats (PubMed:27716508). In response to cytosolic calcium increase, the heterodimer formed with PEF1 interacts with, and bridges together the BCR(KLHL12) complex and SEC31 (SEC31A or SEC31B), promoting monoubiquitination of SEC31 and subsequent collagen export, which is required for neural crest specification (PubMed:27716508). Involved in the regulation of the distribution and function of MCOLN1 in the endosomal pathway (PubMed:19864416). Promotes localization and polymerization of TFG at endoplasmic reticulum exit site (PubMed:27813252). Required for T-cell receptor-, Fas-, and glucocorticoid-induced apoptosis (By similarity). May mediate Ca(2+)-regulated signals along the death pathway: interaction with DAPK1 can accelerate apoptotic cell death by increasing caspase-3 activity (PubMed:16132846). Its role in apoptosis may however be indirect, as suggested by knockout experiments (By similarity). May inhibit KDR/VEGFR2-dependent angiogenesis; the function involves inhibition of VEGF-induced phosphorylation of the Akt signaling pathway (PubMed:21893193). In case of infection by HIV-1 virus, indirectly inhibits HIV-1 production by affecting viral Gag expression and distribution (PubMed:27784779)

The "PDCD6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDCD6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets